Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Sujatha Murali"'
Publikováno v:
Current Breast Cancer Reports. 2:114-119
Growth factor receptor signaling plays a key role in endocrine resistance to therapy for metastatic breast cancer. These molecular pathways provide a unique target for new therapeutic approaches to reverse resistance. In this review, we provide a bac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9483624a68d629bef0860d5488671cf9
https://doi.org/10.1007/s12609-010-0002-8
https://doi.org/10.1007/s12609-010-0002-8
Autor:
Jonathan L. Kaufman, H.J. Khoury, Martha Arellano, Leonard T. Heffner, Edmund K. Waller, M.J. Lechowicz, Sujatha Murali, Amelia Langston, Sagar Lonial, Karen P. Mann, Elliot F. Winton, Chris I. Flowers
Publikováno v:
Bone marrow transplantation. 42(8)
Autologous hematopoietic progenitor SCT (HPCT) has been studied both as a consolidative and salvage maneuver in mantle-cell lymphoma (MCL), and may improve failure-free survival rates as well as overall survival. We describe 21 patients with MCL who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf038119e294b9c79fe75d3cb6af86d
https://pubmed.ncbi.nlm.nih.gov/18622414
https://pubmed.ncbi.nlm.nih.gov/18622414
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-15 (2021)
Abstract Background CD40-CD40L is a key co-stimulatory pathway for B cell activation. As such, its blockade can inhibit pathogenic B cell responses in autoimmune diseases, such as Sjogren’s syndrome (SjS) and systemic lupus erythematosus (SLE). In
Externí odkaz:
https://doaj.org/article/d5f8b1657d3948688062127b0b239635
Autor:
Elisavet Paplomata, Yuan Liu, Amelia Zelnak, Sujatha Murali, Xiaoxian Li, Geetha D. Vallabhaneni, Ruth O'Regan, Virginia G. Kaklamani
Publikováno v:
Journal of Clinical Oncology. 32:576-576
576^ Background: Increased signaling through growth factor receptor pathways, including HER2, has been demonstrated to play a role in resistance to endocrine therapy. Efficacy of inhibiting HER2 and mTOR in HER2-negative, hormone-resistant breast can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42228d0a90a4214ca3669a0ce209441e
https://doi.org/10.1200/jco.2014.32.15_suppl.576
https://doi.org/10.1200/jco.2014.32.15_suppl.576
Autor:
Taylor L Hickman, Eugene Choi, Kathleen R Whiteman, Sujatha Muralidharan, Tapasya Pai, Tyler Johnson, Avani Parikh, Taylor Friedman, Madaline Gilbert, Binzhang Shen, Luke Barron, Kathleen E McGinness, Seth A Ettenberg, Greg T Motz, Glen J Weiss, Amy Jensen-Smith
Publikováno v:
PLoS ONE, Vol 17, Iss 5, p e0266980 (2022)
PurposeThe solid tumor microenvironment (TME) drives T cell dysfunction and inhibits the effectiveness of immunotherapies such as chimeric antigen receptor-based T cell (CAR T) cells. Early data has shown that modulation of T cell metabolism can impr
Externí odkaz:
https://doaj.org/article/e9bfd0d7932a41a6b4376dcb7b3a2440
Autor:
Amelia Zelnak, Toncred M. Styblo, Yuan Liu, Mary S. Newell, Grant W. Carlson, Ruth O'Regan, Sujatha Murali, Monica Rizzo, Mylin A. Torres, Sheryl G. A. Gabram
Publikováno v:
Journal of Clinical Oncology. 31:562-562
562 Background: Hormone receptor (HR)- positive breast cancer patients (pts) typically have lower pathological responses to pre-operative chemotherapy than HR-negative breast cancers. Objective: We evaluated the pathologic and radiologic response rat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13ee2fb021b24d4428d71ef74c38b036
https://doi.org/10.1200/jco.2013.31.15_suppl.562
https://doi.org/10.1200/jco.2013.31.15_suppl.562
Autor:
Grant W. Carlson, D. Senior-Crosby, William C. Wood, C. Wang, Ruth O'Regan, Toncred M. Styblo, Sujatha Murali, S. Gabram-Mendola, K. M. Davis, Amelia Zelnak
Publikováno v:
Journal of Clinical Oncology. 28:557-557
557 Background: AA patients have a worse outcome from breast cancer than their C counterparts, which is partly explained by their propensity to develop triple negative breast cancers. Additionally,...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84d04588487a297aa256bc7e142f44d5
https://doi.org/10.1200/jco.2010.28.15_suppl.557
https://doi.org/10.1200/jco.2010.28.15_suppl.557
Autor:
Amelia Langston, Mary Jo Lechowicz, Leonard T. Heffner, H. Jean Khoury, Sujatha Murali, Edmund K. Waller, Morgan L. McLemore, Sagar Lonial, Jonathan L. Kaufman, Rajni Sinha, Christopher R. Flowers, Stephanie McMillan, Elliott F. Winton
Publikováno v:
Blood. 112:3644-3644
Advanced myelodysplastic syndrome and secondary or relapsed AML are difficult to treat, with CR rates following standard induction chemotherapy less favorable than those for de novo AML. We examined an induction approach using the anti-CD33-calicheam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::157ea68e9d30acc324e359cc712ec594
https://doi.org/10.1182/blood.v112.11.3644.3644
https://doi.org/10.1182/blood.v112.11.3644.3644
Autor:
Ned Waller, H. Jean Khoury, Mary Jo Lechowicz, Leonard T. Heffner, Stephanie McMillan, Jonathan L. Kaufman, Sagar Lonial, Christopher R. Flowers, Elliott F. Winton, Amelia Langston, Sujatha Murali
Publikováno v:
Blood. 108:1960-1960
Advanced myelodysplastic syndrome and secondary or relapsed AML are difficult to treat, with CR rates following standard induction chemotherapy below those for de novo AML. We are examining a novel induction approach using the anti-CD33-calicheamicin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::154910865c334bc5fe765af42d6049af
https://doi.org/10.1182/blood.v108.11.1960.1960
https://doi.org/10.1182/blood.v108.11.1960.1960
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-1 (2021)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/fc500ca70529451bbed970dcea89168a